Arvinas Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Arvinas Stock Summary

Arvinas competes with C4 Therapeutics, Monte Rosa, Nurix Therapeutics, Foghorn Therapeutics, and Relay Therapeutics. Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut. Arvinas operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 280 people.

Arvinas Key Financial Ratios

Arvinas Key Balance Sheet Accounts

Arvinas Key Cash Accounts

Arvinas Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Arvinas's current stock value. Our valuation model uses many indicators to compare Arvinas value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arvinas competition to find correlations between indicators driving Arvinas's intrinsic value. More Info.Arvinas is rated below average in return on equity category among its peers. It is rated second in return on asset category among its peers . At this time, Arvinas' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Arvinas' earnings, one of the primary drivers of an investment's value.

Arvinas Systematic Risk

Today, most investors in Arvinas Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Arvinas' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Arvinas growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Arvinas help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Arvinas. We use our internally-developed statistical techniques to arrive at the intrinsic value of Arvinas based on widely used predictive technical indicators. In general, we focus on analyzing Arvinas Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Arvinas's daily price indicators and compare them against related drivers.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arvinas. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Arvinas Stock, please use our How to Invest in Arvinas guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arvinas. If investors know Arvinas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arvinas listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Arvinas is measured differently than its book value, which is the value of Arvinas that is recorded on the company's balance sheet. Investors also form their own opinion of Arvinas' value that differs from its market value or its book value, called intrinsic value, which is Arvinas' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arvinas' market value can be influenced by many factors that don't directly affect Arvinas' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Arvinas' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arvinas is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arvinas' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.